A citation-based method for searching scientific literature

Weihao Wang, Lina Zhang, Xiaobei Pei, Qi Pan, Lixin Guo. Diabetes Obes Metab 2020
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Determinants of under-reporting of adverse drug reactions: a systematic review.
Elena Lopez-Gonzalez, Maria T Herdeiro, Adolfo Figueiras. Drug Saf 2009
248
50

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
91
50


Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Peter Ueda, Henrik Svanström, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Björn Pasternak. BMJ 2018
114
50

OpenVigil--free eyeballs on AERS pharmacovigilance data.
Ruwen Böhm, Jan Höcker, Ingolf Cascorbi, Thomas Herdegen. Nat Biotechnol 2012
20
50

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
82
50


Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
Hsien-Yen Chang, Sonal Singh, Omar Mansour, Sheriza Baksh, G Caleb Alexander. JAMA Intern Med 2018
55
50


Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
101
50


Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
182
50

Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of five randomized controlled trials.
Satoshi Miyashita, Toshiki Kuno, Hisato Takagi, Takehiro Sugiyama, Tomo Ando, Nelson Valentin, Yuichi J Shimada, Masaki Kodaira, Yohei Numasawa, Yumiko Kanei,[...]. Diabetes Res Clin Pract 2020
10
50

SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System.
Gian Paolo Fadini, Angelo Avogaro. Lancet Diabetes Endocrinol 2017
80
50

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Chantal Mathieu, Gottfried Rudofsky, Moshe Phillip, Eiichi Araki, Marcus Lind, Niki Arya, Fredrik Thorén, Markus F Scheerer, Nayyar Iqbal, Paresh Dandona. Diabetes Obes Metab 2020
14
50

Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers.
Jeff Y Yang, Tiansheng Wang, Virginia Pate, Emily W Gower, Matthew J Crowley, John B Buse, Til Stürmer. Diabetes Obes Metab 2019
17
50

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

Targeting interleukin-1 in heart disease.
Benjamin W Van Tassell, Stefano Toldo, Eleonora Mezzaroma, Antonio Abbate. Circulation 2013
170
50

From endothelial dysfunction to atherosclerosis.
S Sitia, L Tomasoni, F Atzeni, G Ambrosio, C Cordiano, A Catapano, S Tramontana, F Perticone, P Naccarato, P Camici,[...]. Autoimmun Rev 2010
241
50

Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.
Nikole J Byrne, Nobutoshi Matsumura, Zaid H Maayah, Mourad Ferdaoussi, Shingo Takahara, Ahmed M Darwesh, Jody L Levasseur, James Won Suk Jahng, Dyonne Vos, Nirmal Parajuli,[...]. Circ Heart Fail 2020
29
50

Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
Donato Cappetta, Antonella De Angelis, Loreta Pia Ciuffreda, Raffaele Coppini, Anna Cozzolino, Agostino Miccichè, Carmela Dell'Aversana, Domenico D'Amario, Eleonora Cianflone, Cristina Scavone,[...]. Pharmacol Res 2020
9
50

[AGE-RAGE: a hypothesis or a mechanism?].
Berend Isermann, Angelika Bierhaus, Per M Humpert, Gottfried Rudofsky, Triantafyllos Chavakis, Robert Ritzel, Thoralf Wendt, Michael Morcos, Christian Kasperk, Andreas Hamann,[...]. Herz 2004
7
50

Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis.
Husam Ghanim, Sanaa Abuaysheh, Jeanne Hejna, Kelly Green, Manav Batra, Antione Makdissi, Ajay Chaudhuri, Paresh Dandona. J Clin Endocrinol Metab 2020
16
50

Effects of Dapagliflozin on Endothelial Dysfunction in Type 2 Diabetes With Established Ischemic Heart Disease (EDIFIED).
Nur Aisyah Zainordin, Sharifah Faradilla Wan Muhamad Hatta, Fatimah Zaherah Mohamed Shah, Thuhairah Abdul Rahman, Nurhuda Ismail, Zaliha Ismail, Rohana Abdul Ghani. J Endocr Soc 2019
7
50

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
233
50


Atherosclerosis.
Peter Libby, Julie E Buring, Lina Badimon, Göran K Hansson, John Deanfield, Márcio Sommer Bittencourt, Lale Tokgözoğlu, Eldrin F Lewis. Nat Rev Dis Primers 2019
257
50

The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet.
Ji Hye Han, Tae Jung Oh, Ghayoung Lee, Hyo Jin Maeng, Dong Hwa Lee, Kyoung Min Kim, Sung Hee Choi, Hak Chul Jang, Hye Seung Lee, Kyong Soo Park,[...]. Diabetologia 2017
85
50


Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri T Kato, Michael G Silverman, Ofri Mosenzon, Thomas A Zelniker, Avivit Cahn, Remo H M Furtado, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
180
50

Atherosclerosis.
A J Lusis. Nature 2000
50

Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis.
Shintaro Sakurai, Teruo Jojima, Toshie Iijima, Takuya Tomaru, Isao Usui, Yoshimasa Aso. J Diabetes Complications 2020
2
50

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen,[...]. J Am Coll Cardiol 2018
199
50

Macrophage autophagy plays a protective role in advanced atherosclerosis.
Xianghai Liao, Judith C Sluimer, Ying Wang, Manikandan Subramanian, Kristy Brown, J Scott Pattison, Jeffrey Robbins, Jennifer Martinez, Ira Tabas. Cell Metab 2012
346
50

Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity.
Yihai Liu, Jiamin Xu, Mingyue Wu, Biao Xu, Lina Kang. Lipids Health Dis 2021
2
50

Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1.
Ghazaleh Behnammanesh, Giovanna L Durante, Yash P Khanna, Kelly J Peyton, William Durante. Redox Biol 2020
7
50

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.
So Ra Kim, Sang-Guk Lee, Soo Hyun Kim, Jin Hee Kim, Eunhye Choi, Wonhee Cho, John Hoon Rim, Inhwa Hwang, Chan Joo Lee, Minyoung Lee,[...]. Nat Commun 2020
28
50

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.
Antonius Baartscheer, Cees A Schumacher, Rob C I Wüst, Jan W T Fiolet, Ger J M Stienen, Ruben Coronel, Coert J Zuurbier. Diabetologia 2017
212
50

T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes.
A Oku, K Ueta, K Arakawa, T Ishihara, M Nawano, Y Kuronuma, M Matsumoto, A Saito, K Tsujihara, M Anai,[...]. Diabetes 1999
149
50

Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice.
Jan Pennig, Philipp Scherrer, Mark Colin Gissler, Nathaly Anto-Michel, Natalie Hoppe, Lisa Füner, Carmen Härdtner, Peter Stachon, Dennis Wolf, Ingo Hilgendorf,[...]. Sci Rep 2019
9
50

Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review.
Soghra Rabizadeh, Manouchehr Nakhjavani, Alireza Esteghamati. Int J Endocrinol Metab 2019
12
50

Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice.
Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, Eiji Kurosaki. Eur J Pharmacol 2017
21
50

Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes.
Michael J Kraakman, Man Ks Lee, Annas Al-Sharea, Dragana Dragoljevic, Tessa J Barrett, Emilie Montenont, Debapriya Basu, Sarah Heywood, Helene L Kammoun, Michelle Flynn,[...]. J Clin Invest 2017
77
50

Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation.
Alex Ali Sayour, Sevil Korkmaz-Icöz, Sivakkanan Loganathan, Mihály Ruppert, Viktor Nabil Sayour, Attila Oláh, Kálmán Benke, Maik Brune, Rita Benkő, Eszter Mária Horváth,[...]. J Transl Med 2019
33
50

Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges.
M Odette Gore, Darren K McGuire, Ildiko Lingvay, Julio Rosenstock. Curr Cardiol Rep 2015
17
50


Ferritin in atherosclerosis.
Sun-Ah You, Qing Wang. Clin Chim Acta 2005
69
50

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Yuliya Lytvyn, Petter Bjornstad, Jacob A Udell, Julie A Lovshin, David Z I Cherney. Circulation 2017
173
50


Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Mark C Petrie, Subodh Verma, Kieran F Docherty, Silvio E Inzucchi, Inder Anand, Jan Belohlávek, Michael Böhm, Chern-En Chiang, Vijay K Chopra, Rudolf A de Boer,[...]. JAMA 2020
71
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.